These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 9187504)

  • 1. The effect of chemical anti-inhibitors on fibrinolytic enzymes and inhibitors.
    Sidelmann J; Jespersen J; Kluft C; Gram J
    Clin Chim Acta; 1997 May; 261(1):43-56. PubMed ID: 9187504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cleavage of surfactant-incorporating fibrin by different fibrinolytic agents. Kinetics of lysis and rescue of surface activity.
    Günther A; Markart P; Kalinowski M; Ruppert C; Grimminger F; Seeger W
    Am J Respir Cell Mol Biol; 1999 Dec; 21(6):738-45. PubMed ID: 10572071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibrinolysis in health and disease: severe abnormalities in systemic lupus erythematosus.
    Glas-Greenwalt P; Kant KS; Allen C; Pollak VE
    J Lab Clin Med; 1984 Dec; 104(6):962-76. PubMed ID: 6239000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The susceptibility of plasma to activation of fibrinolysis.
    Stief TW
    Blood Coagul Fibrinolysis; 1993 Feb; 4(1):123-5. PubMed ID: 8457639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. On the target specificity of plasminogen activator inhibitor 1: the role of heparin, vitronectin, and the reactive site.
    Keijer J; Linders M; Wegman JJ; Ehrlich HJ; Mertens K; Pannekoek H
    Blood; 1991 Sep; 78(5):1254-61. PubMed ID: 1715220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of oxidants on proteases of the fibrinolytic system: possible role for methionine residues in the interaction between tissue type plasminogen activator and fibrin.
    Stief TW; Martín E; Jimenez J; Digón J; Rodriguez JM
    Thromb Res; 1991 Feb; 61(3):191-200. PubMed ID: 1827545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonradical excited oxygen species induce selective thrombolysis in vivo.
    Stief TW
    Thromb Res; 1991 May; 62(3):147-63. PubMed ID: 1716380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Tissue type plasminogen activator and its inhibition in blood of patients operated on for prostatic carcinoma].
    Iwan-Zietek I; Zietek Z; Kotschy M; Rość D; Tyloch F
    Pol Tyg Lek; 1996 Feb; 51(6-9):91-3. PubMed ID: 8756741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of the polyphenols of cider on plasmin and plasminogen activators.
    Ogston D; Lea AG; Langhorne P; Wilson SB
    Br J Haematol; 1985 Aug; 60(4):705-13. PubMed ID: 3161536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxidative inactivation of plasmin and other serine proteases by copper and ascorbate.
    Lind SE; McDonagh JR; Smith CJ
    Blood; 1993 Sep; 82(5):1522-31. PubMed ID: 8364203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The fibrinolytic mechanism of defibrotide: effect of defibrotide on plasmin activity.
    Echart CL; Graziadio B; Somaini S; Ferro LI; Richardson PG; Fareed J; Iacobelli M
    Blood Coagul Fibrinolysis; 2009 Dec; 20(8):627-34. PubMed ID: 19809307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of fibrinolytic enzymes by thrombin inhibitors.
    Gilboa N; Villannueva GB; Fenton JW
    Enzyme; 1988; 40(2-3):144-8. PubMed ID: 2971531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A long-acting PAI-1 inhibitor reduces thrombus formation.
    Peng S; Xue G; Gong L; Fang C; Chen J; Yuan C; Chen Z; Yao L; Furie B; Huang M
    Thromb Haemost; 2017 Jun; 117(7):1338-1347. PubMed ID: 28405670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reaction of thrombin and proteinases of the fibrinolytic system with a mechanism-based inhibitor, 3,4-dihydro-3-benzyl-6-chloromethylcoumarin.
    Mor A; Maillard J; Favreau C; Reboud-Ravaux M
    Biochim Biophys Acta; 1990 Mar; 1038(1):119-24. PubMed ID: 2138500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant human C1-inhibitor prevents non-specific proteolysis by mutant pro-urokinase during optimal fibrinolysis.
    Gurewich V; Pannell R
    Thromb Haemost; 2009 Aug; 102(2):279-86. PubMed ID: 19652878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of heparin and a low molecular weight heparinoid on specific endogenous and exogenous fibrinolytic factors during rest and exercise.
    de Boer A; Kluft C; Dooijewaard G; Kasper FJ; Kroon JM; Breimer DD; Stiekema JC; Cohen AF
    Thromb Haemost; 1992 Nov; 68(5):550-5. PubMed ID: 1280862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Structure, function and use of fibrinolysis-promoting and inhibiting factors].
    Bachmann F
    Arzneimittelforschung; 1988 Mar; 38(3A):474-8. PubMed ID: 3134901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selection of S18326 as a new potent and selective boronic acid direct thrombin inhibitor.
    Rupin A; Mennecier P; Lila C; de Nanteuil G; Verbeuren TJ
    Thromb Haemost; 1997 Oct; 78(4):1221-7. PubMed ID: 9364988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serine-proteases as plasminogen activators in terms of fibrinolysis.
    Flemmig M; Melzig MF
    J Pharm Pharmacol; 2012 Aug; 64(8):1025-39. PubMed ID: 22775207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complementary modes of action of tissue-type plasminogen activator and pro-urokinase by which their synergistic effect on clot lysis may be explained.
    Pannell R; Black J; Gurewich V
    J Clin Invest; 1988 Mar; 81(3):853-9. PubMed ID: 2963831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.